Markets:

Overview

News

Currencies

International

Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

7.730 -0.070 (-0.90%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Evolus Reports Second Quarter 2023 Results and Provides Business Update

August 02, 2023

From Evolus

Via Business Wire

Earnings Preview: Evolus ↗

August 01, 2023

Via Benzinga

5 Analysts Have This to Say About Evolus ↗

July 28, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 27, 2023

Via Benzinga

Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action

July 27, 2023

Via Investor Brand Network

Why Shares of Evolus Are Jumping Thursday ↗

July 27, 2023

The stock climbed on record second-quarter revenue and a raise in full-year guidance.

Via The Motley Fool

Expert Ratings for Evolus ↗

May 26, 2023

Via Benzinga

This Analyst Likes Evolus As 'Top Play In Aesthetics' ↗

May 10, 2023

Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S.

Via Benzinga

Expert Ratings for Evolus ↗

May 10, 2023

Via Benzinga

Evolus: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 27, 2023

Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.

Via Benzinga

Comcast, STMicroelectronics, Lam Research, Meta Platforms And Other Big Stocks Moving Higher On Thursday ↗

July 27, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

July 27, 2023

From Evolus

Via Business Wire

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

July 26, 2023

From Evolus, Inc.

Via Business Wire

Evolus to Report Second Quarter 2023 Results and Provide Business Update

July 19, 2023

From Evolus

Via Business Wire

Twitter Faces Threats From AI and Threads ↗

July 15, 2023

AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience.

Via The Motley Fool

Evolus Earnings Preview ↗

May 08, 2023

Via Benzinga

Analyst Expectations for Evolus's Future ↗

March 09, 2023

Via Benzinga

Preview: Evolus's Earnings ↗

March 07, 2023

Via Benzinga

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

June 29, 2023

From Evolus

Via Business Wire

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

June 22, 2023

From Evolus

Via Business Wire

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

June 08, 2023

From Evolus

Via Business Wire

Evolus Reports First Quarter 2023 Results and Provides Business Update

May 09, 2023

From Evolus

Via Business Wire

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

May 09, 2023

From Evolus, Inc.

Via Business Wire

Evolus to Report First Quarter 2023 Results and Provide Business Update

May 05, 2023

From Evolus, Inc.

Via Business Wire

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 08, 2023

From Evolus

Via Business Wire

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Evolus to Participate in the Barclays Global Healthcare Conference

February 28, 2023

From Evolus

Via Business Wire

Evolus Initiates Nuceiva® Launch in Germany and Austria

February 27, 2023

From Evolus, Inc.

Via Business Wire

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

February 22, 2023

From Evolus

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Evolus, Inc. - Common Stock (NQ:EOLS)

All News about Evolus, Inc. - Common Stock

Starting at /week.